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Highlights 
 Early nurse specialist contact is associated with greater receipt of therapy 
 Receipt of surgery is less likely where nurse specialists have large caseloads 
 Therapy receipt is more likely if key nursing interventions are routinely provided 
 Managing nurse specialists’ workload could address disparities in therapy uptake 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
 Abstract 
Objectives: Treatment choices for people with lung cancer may be influenced by contact and 
engagement with lung cancer nurse specialists (LCNSs). We investigated how service factors, LCNS 
workload, and LCNS working practices may influence the receipt of anticancer treatment. 
Materials and methods: English National Lung Cancer Audit data and inpatient Hospital Episode 
Statistics for 109,079 people with lung cancer surviving 30 days from diagnosis were linked along 
with LCNS workforce census data and a bespoke nationwide LCNS survey. Multinomial logistic 
regression was used to determine adjusted relative risk ratios (RRRs) for receipt of anticancer 
therapies associated with LCNS assessment, LCNS workforce composition, caseload, LCNS reported 
working practices, treatment facilities at the patients’ attending hospitals, and the size of the lung 
cancer service. 
Results: Assessment by an LCNS was the strongest independent predictor for receipt of anticancer 
therapy, with early LCNS assessments being particularly associated with greater receipt of surgery 
(RRR 1.85, 95%CI 1.63–2.11). For people we considered clinically suitable for surgery, receipt was 
55%. Large LCNS caseloads were associated with decreased receipt of surgery among suitable 
patients (RRR 0.71, 95%CI 0.51–0.97) for caseloads >250 compared to ≤150. Reported LCNS working 
practices were associated with receipt of surgery, particularly provision of psychological support 
(RRR 1.60, 95%CI 1.02–2.51) and social support (RRR 1.56, 95%CI 1.07–2.28).  
Conclusion: LCNS assessment, workload, and working practices are associated with the likelihood 
of patients receiving anticancer therapy. Enabling and supporting LCNSs to undertake key case 
management interventions offers an opportunity to improve treatment uptake and reduce the 
apparent gap in receipt of surgery for those suitable.  
Keywords: Lung cancer; Nurse specialists; Treatment; Workload; Case management; Clinical Audit   
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 1.0. Introduction 
A diagnosis of lung cancer is often associated with a poor prognosis because of its frequent 
identification at an advanced disease stage and the rapid decline in performance status; as such it 
has the highest mortality of all cancers [1,2]. Improvement in survival in the UK has been greater 
than in other high-income countries globally [3], although relative survival is reported to be lower 
than in other parts of Europe [4]. 
Increased uptake of treatment is crucial to drive improvements in lung cancer survival. The 2016 
National Lung Cancer Audit (NLCA) reported improvements in the proportions of people with non-
small-cell lung cancer (NSCLC) undergoing surgery and those with small-cell lung cancer (SCLC) 
receiving chemotherapy compared with those in previous years, but concluded that there was an 
unexplained variation in surgical resection rates; the majority of hospital providers did not meet a 
60% target for the proportion of people receiving anticancer treatment (in the form of surgery, 
chemotherapy or radiotherapy) [5]. 
Previous studies have identified specific hospital-provider and patient factors associated with 
inequalities in access  and uptake of lung cancer treatment across England [6-10], with similar 
characteristics shown to have an influence internationally [11]. We have previously shown that such 
factors are also associated with a patient’s likelihood of assessment by a lung cancer nurse specialist 
(LCNS) [12]. Guidelines from the National Institute for Health and Care Excellence (NICE) 
recommend that patients have direct access to an LCNS for support throughout the cancer pathway 
[13]; NLCA annual reports show improvement over time in the proportion of patients seen by a 
nurse specialist, although recommended targets are not always met [14,15]. LCNSs have a crucial 
role in an individual’s cancer journey as experienced professionals who case manage care, meet 
information needs, manage symptom control issues, support patients and families in decision-
making and readiness for treatment, and advocate patient wishes within multidisciplinary settings 
[16,17]. However, whether these working practices are directly linked with treatment uptake has 
not been assessed. 
To understand how contact with an LCNS may influence a person’s decision for anticancer therapy, 
we assessed whether factors affecting LCNS workload are associated with receipt in an English lung 
cancer population and, in particular, those who could be expected to undergo surgical resection. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 2.0. Materials and methods 
NLCA data capturing cases of lung cancer diagnosed at hospital providers across the UK were linked 
with the 2011 National Cancer Action Team (NCAT) census of specialist cancer nurse workforces in 
England by hospital provider (National Health Service trust) code [18], and hospital episode 
statistics (HES) inpatient data according to NHS number provided the official record of admission 
episodes to NHS hospital trusts. We included NLCA patients from 146 English hospital providers who 
were first seen between January 2007 and December 2011 at a service with NCAT workforce data 
verified by regional cancer network (Appendix A). People diagnosed through death certificates only 
and those with mesothelioma or carcinoid were not included. We also excluded people who died 
within 30 days of their diagnosis as it is likely they were at a very advanced stage upon diagnosis 
and therefore did not have an opportunity to commence anticancer therapy or be assessed by an 
LCNS. 
A combination of the NLCA and HES—where dates of surgery, chemotherapy and radiotherapy are 
recorded [19]—was used to assign people to one of four exclusive categories: surgery with or 
without chemotherapy or radiotherapy, chemotherapy with or without radiotherapy, radiotherapy 
alone, or no anticancer therapies. All chemotherapy and radiotherapy treatments were then 
combined for subgroup analysis. Whether radiotherapy was of curative or palliative intent was not 
distinguished because detail to definitively determine this was not available. 
NLCA and HES data classified specialist anticancer treatment facilities available at each hospital 
provider: thoracic surgery facilities (surgical), chemotherapy available without surgery 
(chemotherapy), or neither treatment option onsite (no specialty). A hospital provider with a 
specialty in chemotherapy was defined by at least 75% of patients receiving an anticancer drug at a 
service where they were also first seen, as previously described by Powell et al. [8]. NLCA data were 
used to determine the annual number of new lung cancer patients seen by a service in each year of 
the study, with an average providing a measure of service size. 
Using NCAT national census information on salary bands, we categorized the composition of LCNS 
workforces as Band 7 only, Bands 6–7 or Band 8 included. Each hospital provider’s LCNS caseload 
was calculated as the total number of patients first seen there divided between the LCNS whole-
time equivalent (WTE) workforce, assuming people followed the lung cancer pathway at that same 
site [12]. Evidence about whether the patient was assessed by an LCNS was obtained from NLCA 
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 data, as was the timing of assessment relative to diagnosis. Where no information was entered, 
patients were separately categorized as missing and were included in the analyses.  
2.1. Statistical analysis 
There were three or more possibilities for the receipt of treatment. We performed multinomial 
logistic regression using Stata (SE15) to calculate the relative risk ratio (RRR) of receipt of specified 
therapies relative to a base group of no anticancer therapy. The RRR is sometimes interpreted as a 
conditional odds ratio or called a multinomial odds ratio.  Cluster robust standard errors were 
derived to calculate confidence intervals for RRRs using regional cancer networks to account for 
hierarchical groupings of observations. Exposure variables were individual patient-recorded LCNS 
assessment and its timing, salary band composition of the LCNS workforce, the average LCNS 
caseload at the service, treatment facilities available, and the annual service size. Univariate 
analyses were performed, and models were mutually adjusted for exposures as well as patient co-
morbidity defined using HES IP ICD-10 codes [20], age at diagnosis, sex, socioeconomic quintile 
(based on income deprivation domain for the national population), performance status, and cancer 
stage as recorded in the NLCA.  
As receipt of treatment is influenced by a number of factors that we were unable to control for, we 
conducted a subgroup analysis restricted to people who we deemed were suitable for surgery based 
on clinical guidelines and author expertise (RBH, PB) and the clinical data available to us. Suitability 
for surgery was defined as a recorded performance status of 0–1 (World Health Organization, WHO) 
and NSCLC stages I, II, IIIA (Union for International Cancer Control versions 6 and 7) [20]. 
For people who were suitable for surgery, receipt of therapy was also assessed according to LCNS-
reported experiences of working practice by using responses from a bespoke e-survey disseminated 
to all LCNSs in the UK’s National Lung Cancer Forum for Nurses (NLCFN) (Appendix B). A total of 230 
survey responses from 105 hospital providers were collected; the response rate was estimated to 
be 76% of WTE LCNS positions in England [21], with a completion rate for questions presented here 
ranging from 83% to 100%. Responses were linked to the combined dataset based on the NHS trust 
code where the LCNS worked. Routine provision of key LCNS interventions was defined as offered 
to more than 70% of patients along the clinical pathway from pre-diagnosis up to and including the 
point of treatment. As the role of the LCNS can vary widely, affirmative responses were aggregated 
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 according to hospital provider to present the perspective of at least one LCNS and an indication of 
key interventions available to the patient population served. 
3.0. Results 
A total of 109,079 patients in our study population were diagnosed with lung cancer between 2007 
and 2011 and survived 30 days; of these, 31.8% did not receive anticancer therapy, 33.9% received 
chemotherapy, 18.3% received radiotherapy, and 16.1% received surgery (Table 1).  
3.1. LCNS workforce factors 
Assessment by an LCNS was associated with increased RRR in receipt of each therapy group 
compared to not being assessed (surgery RRR 1.98, chemotherapy RRR 2.18, radiotherapy RRR 1.84 
after adjustments). LCNS assessment before/at diagnosis also resulted in an increased RRR in each 
therapy group compared to assessment after diagnosis, particularly for surgery (RRR 1.85 95%CI 
1.63–2.11). Where workforces included a Band-8 LCNS, there was an associated 27% reduction in 
RRR for receipt of chemotherapy (RRR 0.73, 95%CI 0.54–0.97), whilst average caseloads of >250 
patients per LCNS were associated with a 26% increase in the RRR for receipt of radiotherapy (RRR 
1.26, 95%CI 1.00-1.59). 
3.2. Hospital-provider factors 
Specialist anticancer treatment facilities were associated with greater RRRs for receipt of each 
therapy group compared to services with no specialty, availability of surgical facilities resulting in 
the greatest associations (surgery RRR 1.80; chemotherapy RRR 1.81; radiotherapy RRR 1.47 after 
adjustments). Availability of specialist chemotherapy facilities was associated with a greater RRR for 
receipt of chemotherapy (RRR 1.39, 95%CI 1.10–1.75) and radiotherapy (RRR 1.27, 95%CI 1.05–
1.53), but no association was observed for receipt of surgery. The annual service size was not 
associated with receipt. 
3.3. Clinical suitability for surgical resection 
Our subgroup criteria identified 17,213 patients (15.8% of all patients) suitable for surgery based 
on cancer stage and performance status; 54.7% of people within this subgroup received surgery and 
11.1% received no anticancer therapy (Table 2). For those suitable for surgery, timing of LCNS 
assessment before/at diagnosis was strongly associated with its receipt (RRR 1.68, 95%CI 1.36–
2.07). Large LCNS caseloads of >250 new and surviving patients were associated with lower RRR for 
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 receipt of surgery (RRR 0.71, 95%CI 0.51–0.97). Surgical facilities were associated with a 60% 
increase in RRR compared to no specialty (RRR 1.60, 95%CI 1.22–2.08), whilst services which saw 
265 new patients per year were associated with receipt of the alternative therapy option of 
chemotherapy or radiotherapy (RRR 1.32, 95%CI 1.01–1.71).  
The association between LCNS-reported working practices and receipt of treatment was analyzed 
in 13,588 people who were suitable for surgery, survived 30 days, and were represented by a 
response to a national LCNS survey (Table 3). Availability of administrative support was not 
associated with receipt of surgery, nor were provision of proactive management, holistic needs 
assessment or investigation management. Provision of health promotion was associated with a 29% 
increase in RRR for surgery (RRR 1.29, 95%CI 1.01–1.65), whilst routine provision of social support 
was associated with a 56% increase in receipt of surgery (RRR 1.56, 95%CI 1.07–2.28). Where 
psychological support was routinely offered, there was an associated increase in RRR of receiving 
surgery (RRR 1.60, 95%CI 1.02–2.51) and the alternative therapy options (RRR 1.44, 95%CI 1.15–
1.81). Where LCNS teams reported readiness to challenge any member within the multidisciplinary 
team, there was an associated increase in the RRR for receipt of the alternative therapy options 
(RRR 1.44, 95%CI 1.07–1.93), although receipt of surgery did not reach significance (RRR 1.49, 95%CI 
0.93–2.39).  
4.0. Discussion 
Advanced nursing practice in cancer care offers tremendous advantages through provision of 
cancer-specific expertise, leadership and continuity across the whole care pathway. Despite their 
complex skillsets, few data exist to quantify the impact of LCNSs on clinical outcomes, and methods 
to do so require cautious interpretation. Utilizing a large dataset representative of people with 
newly diagnosed lung cancer [22], linked to hospital records and survey data, we observed that 
assessment by an LCNS, assessment before/at diagnosis, and the availability of specialist surgical 
facilities at a hospital provider were the strongest independent predictors from resource-specific 
factors for the receipt of anticancer therapy. This observation was particularly true for receipt of 
surgery. Where the individual may be considered suitable for surgery, caseloads >250 new and 
surviving patients per LCNS were associated with reduced likelihood of surgery, whilst provision of 
key interventions were associated with greater receipt. 
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 4.1. Strengths and limitations 
Our robust multinomial models are adjusted for patient sociodemographic and disease factors that 
may be important confounders, as well as organizational factors such as caseload and service 
specialty. To address immortal time bias, the analysis was restricted to patients surviving 30 days 
post-diagnosis. To address differences in therapy suitability within a heterogeneous lung cancer 
population, subgroup criteria were selected according to clinical suitability for surgery.  
Linkage to a nationwide LCNS survey adds further insight into LCNS working practices at the level of 
hospital provider; however, aggregation of responses may not represent the experiences of all 
LCNSs or their caseloads. Those who did not respond to the survey may suffer greater time 
pressures.  
Our analyses support LCNS assessments as an important aspect in improving the receipt of 
treatment, although we could not distinguish in our data whether contact with an LCNS was a 
consequence of a decision to start treatment, even when the LCNS assessment preceded treatment. 
Other resource-related factors were assessed to further elucidate the impact of the LCNS workforce 
on receipt of treatment. 
We found missing data on LCNS assessment for 31% of all patients. It has previously been shown 
that the percentage of missing data reduced during the study period from 32% in 2007 to 10% in 
2011 [12], which may introduce bias through differences in working practices over time. The 
number of people without an initial LCNS assessment is reassuringly low relative to those assessed 
or those missing data; however, this discrepancy may overestimate the impact of the initial LCNS 
assessment, and we considered further measures of LCNS involvement and working practice on 
receipt of treatment. 
The linked dataset of people surviving 30 days included a total of 17,549 people who received 
surgery, of whom 21.5% did not have a recorded performance status and 17.9% were missing a 
complete cancer stage entry. People suitable for surgery without a recorded performance status or 
cancer stage were not included in the restricted analysis, although our inclusion criteria provided 
the highest proportion of recipients compared to more liberal definitions. 
4.2. Hospital provider context and receipt of anticancer therapy 
People were more likely to be in receipt of therapy if first seen in a service with specialist anticancer 
treatment facilities. This was similarly true when the people considered were restricted to those 
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 suitable for surgery, with the specific finding that specialist surgical facilities were associated with 
greater receipt of surgery. A potential explanation is that resources at such services may focus on 
patients who have the potential to benefit most from therapy, yet this raises questions of inequality 
and adds to studies that identify discrepancies in patient resection rates according to the proximity 
of surgical facilities [6,9].  
4.3. LCNS assessment and receipt of anticancer therapy 
We have previously shown that receipt of treatment is associated with LCNS assessment and early 
timing of assessment [12]. Here, we determined the impact of service factors and LCNS working 
practices on treatment receipt, and we restricted analyses to those who should be considered 
suitable for surgery. The observation that resection was more likely if assessed by an LCNS before/at 
diagnosis may reflect a discrepancy in patient confidence and knowledge around surgical options 
when LCNS assessment and opportunity for intervention precedes diagnosis [20,23]. LCNSs have 
excellent understanding of patient context and requirements to improve eligibility for therapies, 
and they act as a constant supportive presence [16]; this is particularly important when there may 
be anxiety regarding treatment risks [23]. This analysis provides evidence that timely LCNS 
assessment before/at diagnosis offers the best chance for everyone with a lung cancer diagnosis to 
receive the most appropriate therapy.  
4.4. LCNS working practices and receipt of anticancer therapy 
Inclusion of Band-8 LCNSs reduced the chances of receipt of chemotherapy in the overall 
population, whilst the proportion of people who did not receive therapy was also relatively large. It 
is possible that nurses may be more receptive to an individual’s preference for no therapy, 
supporting their decision and advocating it within multidisciplinary settings [16]. The confidence 
required to support alternative decisions is likely an attribute of highly qualified and experienced 
LCNSs [24].  
In the subgroup analysis, associations were found with the key LCNS roles of health promotion, 
psychological support and social support (e.g. signposting financial advice), providing evidence that 
the ability to support patients and direct them to further sources of assistance can increase the 
likelihood of surgical resection. LCNS confidence within the multidisciplinary team was associated 
with increased patient receipt of other therapies in the suitability subgroup, suggesting that LCNS 
confidence and multidisciplinary team inclusivity are important in encouraging patients’ receipt of 
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 treatment, although its influence on receipt of surgery in those with underlying suitability did not 
reach confidence levels.  
Administrative support was not associated with differences in receipt of surgery for those suitable, 
where provision may be expected to be associated with increased receipt, particularly as the 
pressure of large caseloads are associated with reduced receipt. However, nurses frequently go 
beyond their contractual hours to avoid pressures that could affect patient outcomes. Such 
dedication may obscure the true impact of administrative support on patients’ receipt of treatment. 
4.5. Improving treatment uptake 
The 2016 NLCA report notes improvement in recent years in the number of surgical operations in 
people with NSCLC, but notes substantial variation across hospital providers [5]. Though clinical 
detail was limited, we identified people who were broadly suitable for surgery (16% of our cohort), 
yet only 55% received it. Improving uptake in suitable patients alone presents an opportunity to 
improve upon treatment rates and highlights the gap between suitability and patient preference.  
Where surgery was a suitable option, likelihood of receipt was almost 30% lower at services with 
LCNS caseloads >250 compared to those where caseloads were <150 people. These data indicate 
that the largest caseloads impede decisions for surgery and may not offer sufficient time to appease 
concerns regarding treatment risks [23], regardless of suitability.  
In 2014, The LCNS workforce was estimated at 263 WTE positions in England [21], equating to 
caseloads of 117 new patients, with 47 more having survived the preceding year at a 1-year survival 
rate of 38% [5], totalling 164 patients on each LCNS caseload if shared equally between all WTE 
positions. This figure is likely to vary drastically between providers and regions; indeed 23% of our 
English cross-section were seen where caseloads were >250 people. We recommend ensuring that 
WTE positions represent 1% of the expected new lung cancer incidence, enabling caseloads of <150 
managed patients (new and surviving), closely aligned to NLCFN guidance (new only) [25].  
Caseload pressure may also be reduced by assistance from clinical support workers and through 
LCNS delegation of routine clerical tasks to care coordinators [26]. Reducing caseload pressures 
could offer sufficient time for well-informed individual treatment decisions and assure access to 
psychological and social support, and could allow further LCNS focus on symptom and pathway 
management to facilitate optimal treatment. The relationship between specialist nurse staffing 
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 levels and optimal caseload is a challenge to simulate in a complex patient group; our findings can 
contribute to current and future models [27,28]. 
4.6. Conclusion 
Championing the LCNS role is an appropriate strategy to improve treatment rates, as contact and 
working practices are associated with receipt of treatment, potentially via improved patient 
comprehension of the disease and engagement with options. We propose that enabling and 
supporting LCNSs to undertake key case-management duties, whilst monitoring WTE working hours 
relative to manageable caseload sizes, could reduce workload pressures sufficiently to improve 
treatment uptake in all lung cancer diagnoses, highlighted in those who are clinically suitable. 
Future studies should further elucidate patient reasons for refusal of optimal treatment strategies.  
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 Table 1: Lung cancer nurse specialist (LCNS) workload factors and their associations with receipt of 
anticancer therapy 
 Total 
No 
thera
py 
Receipt of 
surgery 
Receipt of 
chemotherapy 
Receipt of 
radiotherapy 
 
n = 
109,079 
n = 
34,72
9 n = 17,459 n = 36,951 n = 19,940 
 Freq % % % 
RRR
* 
(95% 
CI) % 
RRR
* 
(95% 
CI) % 
RRR
* 
(95% 
CI) 
Assessed by 
LCNS                         
No 
4,73
0 4.3 8.0 3.3 1   2.0 1   3.3 1   
Yes 
70,9
04 
65.
0 57.3 
65.
4 
1.9
8 
(1.11
–
3.53) 
70.
7 
2.1
8 
(1.24
–
3.82) 
68.
9 
1.8
4 
(1.17
–
2.87) 
Missing 
33,4
45 
30.
7 36.0 
31.
3 
1.7
3 
(1.32
–
2.26) 
27.
3 
2.1
4 
(1.67
–
2.75) 
27.
8 
1.7
2 
(1.41
–
2.10) 
                     
First LCNS 
assessment                   
After 
diagnosis 
30,5
78 
28.
0 28.4 
20.
2 1   
30.
1 1   
31.
1 1   
Before/at 
diagnosis 
36,9
95 
33.
9 25.7 
41.
5 
1.8
5 
(1.63
–
2.11) 
37.
8 
1.2
7 
(1.14
–
1.42) 
34.
9 
1.1
6 
(1.05
–
1.28) 
Missing 
41,5
06 
38.
1 47.2 
38.
3 
1.4
1 
(0.93
–
2.14) 
32.
1 
0.7
4 
(0.52
–
1.07) 
34.
0 
0.8
1 
(0.56
–
1.18) 
                     
LCNS 
workforce                   
Band 7 only 
47,2
44 
43.
3 43.7 
44.
0 1   
44.
4 1   
40.
9 1   
Bands 6–7 
46,6
77 
42.
8 42.7 
41.
6 
0.9
4 
(0.76
–
1.16) 
42.
5 
0.9
7 
(0.78
–
1.20) 
45.
5 
1.1
5 
(0.97
–
1.35) 
Band 8 
included 
15,1
58 
13.
9 14.9 
14.
4 
0.8
1 
(0.57
–
1.14) 
13.
0 
0.7
3 
(0.54
–
0.97) 
13.
7 
0.9
6 
(0.73
–
1.25) 
                     
total LCNS 
caseload                    
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 ≤150 
patients 
22,6
73 
20.
8 21.7 
21.
1 1   
20.
9 1   
37.
3 1   
151–250 
61,2
18 
56.
1 56.4 
56.
3 
0.9
7 
(0.82
–
1.14) 
56.
8 
1.0
8 
(0.87
–
1.33) 
96.
9 
1.0
9 
(0.91
–
1.30) 
>250 
25,1
88 
23.
1 23.2 
22.
5 
0.9
6 
(0.73
–
1.25) 
22.
2 
1.0
0 
(0.78
–
1.28) 
40.
0 
1.2
6 
(1.00
–
1.59) 
                     
Treatment 
facilities                    
No 
specialty 
27,4
99 
25.
2 29.4 
23.
7 1   
22.
8 1   
24.
3 1   
Surgical 
29,6
46 
27.
2 24.0 
31.
9 
1.8
0 
(1.42
–
2.28) 
28.
4 
1.8
1 
(1.45
–
2.26) 
26.
8 
1.4
7 
(1.20
–
1.80) 
Chemother
apy 
51,9
34 
47.
6 47.8 
44.
4 
1.2
2 
(0.95
–
1.56) 
48.
8 
1.3
9 
(1.10
–
1.75) 
48.
9 
1.2
7 
(1.05
–
1.53) 
                     
Annual 
service size                    
<175 new 
LC patients 
39,7
97 
36.
5 37.5 
37.
6 1   
36.
7 1   
34.
1 1   
175–264 
32,9
59 
30.
2 30.5 
28.
4 
0.8
3 
(0.63
–
1.09) 
29.
8 
0.8
7 
(0.67
–
1.15) 
32.
8 
1.0
5 
(0.89
–
1.24) 
≥265 
36,3
23 
33.
3 33.3 
34.
0 
0.8
9 
(0.73
–
1.08) 
33.
5 
0.9
5 
(0.79
–
1.15) 
33.
1 
1.0
3 
(0.86
–
1.23) 
LC, lung cancer. 
* Relative risk ratio adjusted for LCNS assessment and timing, workforce banding, average 
caseload size per LCNS, therapy availability and service size, as well as patient’s age, sex, 
performance status, stage, comorbidity, and socioeconomic deprivation. Clustered by English 
Regional Cancer Network.  
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 Table 2: Lung cancer nurse specialist (LCNS) workload factors and their associations with receipt of 
anticancer therapy among patients considered suitable for surgery 
 Total 
No 
therapy Receipt of surgery Chemotherapy/radiotherapy 
 n = 17,213 n = 1,910 n = 9,417 n = 5,886 
 Freq % % % RRR* (95% CI) % RRR* (95% CI) 
Assessed by LCNS                   
No 549 3.2 5.5 3.4 1   2.1 1   
Yes 13,040 75.8 67.9 74.6 1.74 
(0.93–
3.26) 80.1 1.68 (0.93–3.01) 
Missing 3,624 21.1 26.6 22.0 1.20 
(0.85–
1.96) 17.8 1.43 (0.99–2.06) 
                
First LCNS 
assessment              
After diagnosis 4,500 26.1 27.7 22.2 1   32.0 1   
Before/at diagnosis 8,039 46.7 37.2 49.3 1.68 
(1.36–
2.07) 45.7 1.08 (0.91–1.29) 
Missing 4,674 27.2 35.0 28.6 1.27 
(0.82–
1.96) 22.3 0.64 (0.41–1.01) 
                
LCNS workforce              
Band 7 only 7,049 41.0 43.9 43.6 1   41.9 1   
Bands 6–7 7,377 42.9 40.6 42.7 1.00 
(0.82–
1.23) 43.8 1.12 (0.94–1.34) 
Band 8 included 2,427 14.1 15.5 13.7 0.79 
(0.54–
1.15) 14.3 0.93 (0.59–1.48) 
                
Total LCNS caseload               
≤150 patients 3,583 20.8 18.3 21.7 1   20.2 1   
151–250 9,747 56.6 57.3 56.5 0.83 
(0.66–
1.04) 56.7 0.92 (0.76–1.10) 
>250 3,883 22.6 24.5 21.8 0.71 
(0.51–
0.97) 23.1 0.86 (0.65–1.16) 
                
Treatment facilities               
No specialty 4,016 23.3 26.8 21.9 1   24.5 1   
Surgical 5,241 30.4 24.8 32.9 1.60 
(1.22–
2.08) 28.3 1.27 (0.96–1.68) 
Chemotherapy 7,956 46.2 48.4 45.2 1.15 
(0.86–
1.55) 47.2 1.04 (0.84–1.28) 
                
Annual service size               
<175 new LC 
patients 5,923 34.4 36.3 35.1 1   32.8 1   
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 175–264 5,202 30.2 32.8 28.8 0.88 
(0.71–
1.10) 31.6 1.00 (0.80–1.27) 
≥265 6,088 35.4 30.9 36.1 1.12 
(0.90–
1.40) 35.7 1.32 (1.01–1.71) 
LC, lung cancer. 
* Relative risk ratio adjusted for LCNS assessment and timing, workforce banding, average 
caseload size per LCNS, therapy availability and service size, as well as patient’s age, sex, 
performance status, stage, comorbidity, and socioeconomic deprivation. Clustered by English 
Regional Cancer Network. 
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  Table 3: Lung cancer nurse specialist (LCNS) reported working practices and their associations 
with receipt of anticancer therapy among patients considered suitable for surgery 
 Total 
No 
thera
py Receipt of surgery 
Chemotherapy/radiothe
rapy 
 Freq % % % 
RRR
* 
(95%C
I) % RRR* (95%CI) 
Suitable for surgery (n) 17,213 1,910 9,417 5,886 
Patients represented by 
survey response (n) 13,588 1,393 7,466 4,729 
Administrative  support 
available 6,792 
50.
0 48.2 
50.
6 
1.1
0 
(0.86–
1.39) 49.5 1.01 
(0.83–
1.22) 
                    
Patients represented by 
survey response (n) 13,041 1,337 7,137 4,567 
Proactive management 
routinely provided 
11,05
9 
84.
8 83.4 
84.
0 
1.0
6 
(0.79–
1.43) 86.4 1.21 
(0.85–
1.72) 
                
Holistic needs 
assessment routinely 
provided 
11,90
1 
91.
3 89.1 
91.
7 
1.2
7 
(0.83–
1.95) 91.3 1.28 
(0.73–
2.23) 
                
Health promotion 
routinely provided 
11,73
3 
90.
0 87.2 
90.
7 
1.2
9 
(1.01–
1.65) 89.7 1.23 
(0.90–
1.67) 
                
Investigation 
management routinely 
provided 
12,39
2 
95.
0 94.2 
94.
7 
1.2
2 
(0.85–
1.73) 95.7 1.19 
(0.85–
1.64) 
                
Psychological support 
routinely provided 
12,22
5 
93.
7 90.9 
93.
9 
1.6
0 
(1.02–
2.51) 94.3 1.44 
(1.15–
1.81) 
                
Social support routinely 
provided 
12,83
4 
98.
4 98.1 
98.
4 
1.5
6 
(1.07–
2.28) 98.5 1.31 
(0.91–
1.88) 
                    
Patients represented by 
survey response (n) 7,782 826 4,225 2,731 
LCNS confident 
challenging all MDT 
members 6,366 
81.
8 76.0 
82.
4 
1.4
9 
(0.93–
2.39) 82.6 1.44 
(1.07–
1.93) 
                    
MDT, multidisciplinary team. Routine provision of intervention defined as offered by at least one 
LCNS at service to more than 70% of their caseload from pre-diagnosis to treatment. Negative 
response RRR = 1; affirmative responses presented. 
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 * Relative risk ratio adjusted for LCNS assessment and timing, workforce banding, average 
caseload size per LCNS, therapy availability and service size, as well as patient’s age, sex, 
performance status, stage, comorbidity, and socioeconomic deprivation. Clustered by English 
Regional Cancer Network. 
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